|1.||Tobias, Joseph D: 9 articles (01/2015 - 07/2009)|
|2.||Aronson, Solomon: 5 articles (08/2014 - 10/2007)|
|3.||Varon, Joseph: 5 articles (04/2011 - 03/2009)|
|4.||Lumb, Philip D: 4 articles (08/2014 - 07/2008)|
|5.||Levy, Jerrold H: 4 articles (08/2014 - 05/2002)|
|6.||Dunbar, Lala: 4 articles (04/2014 - 03/2009)|
|7.||Hu, Ming-yi: 4 articles (07/2013 - 01/2012)|
|8.||Sjöquist, Per-Ove: 4 articles (01/2004 - 08/2002)|
|9.||Wang, Yamei: 3 articles (08/2014 - 01/2012)|
|10.||Peacock, W Frank: 3 articles (04/2014 - 03/2009)|
|1.||Hypertension (High Blood Pressure)
06/01/2009 - "In trials like the ESCAPE trials, ECLIPSE, and VELOCITY, clevidipine demonstrated a significant improvement in the management of acute hypertension when compared to placebo as shown in both ESCAPE trials. "
01/01/2009 - "Intravenous clevidipine is effective in the treatment of both acute preoperative and postoperative hypertension in adult cardiac surgery patients, and with a rapid onset and short duration of action the drug can be easily titrated for predictable BP control. "
10/01/2008 - "Clevidipine is an effective agent for reducing acute elevation in blood pressure in various settings, including hypertensive emergencies and perioperative hypertension with a good safety profile."
07/01/2008 - "Clevidipine is effective and safe in the rapid treatment of acute postoperative hypertension after cardiac surgery."
03/01/2009 - "Clevidipine, dosed in a non-weight-based manner, was safe and effective in a cohort of patients with severe hypertension at a starting dose of 2 mg per hour, followed by simple titration during 18 hours or more of continuous infusion. "
01/01/2009 - "Data from animal studies suggest that clevidipine may protect against myocardial and renal injury caused by ischemia and/or reperfusion. "
09/01/2002 - "The difference in infarct size between pigs given clevidipine after 5 or 44 minutes of ischemia was not significant. "
09/01/2002 - "The infarct size, expressed as a percentage of the area at risk, was significantly smaller in pigs given clevidipine after 5 minutes (58 +/- 17%; p < 0.01) and after 44 minutes (42 +/- 6%; p < 0.01) of ischemia than in pigs receiving clevidipine after 35 minutes of ischemia (85 +/- 4%). "
08/01/2002 - "In animals subjected to different periods of ischemia, very low levels of clevidipine were detected in the coronary venous blood only during the first 2 minutes of reperfusion. "
08/01/2002 - "When given locally to the ischemic and reperfused myocardium, clevidipine exerts a cardioprotective effect that varies depending on the timing of administration during ischemia. "
|3.||Acute Kidney Injury (Acute Renal Failure)
01/01/2010 - "Adverse events in these studies included atrial fibrillation (13.0%-36.1% clevidipine vs 12.0% placebo), nausea (5.0%-21.0% vs 12.0%, respectively), fever (19.0% vs 13.7%), insomnia (12.0% vs 6.1%), and acute renal failure (9.0% vs 2.0%). "
05/01/2002 - "Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats."
05/01/2002 - "The present studies were conducted to: a) comparatively evaluate the effects of clevidipine, a new dihydropyridine calcium antagonist, and fenoldopam, a dopamine (D-1) receptor agonist on basal renal function, and b) to determine the efficacy of these agents in protecting renal function in an experimental model of ischemia/reperfusion (I/R) induced acute renal failure in rats. "
01/01/2013 - "Clevidipine rapidly and safely reduces blood pressure in acute intracerebral hemorrhage: the ACCELERATE trial."
01/01/2013 - "ACCELERATE (the Evaluation of Patients with Acute Hypertension and Intracerebral Hemorrhage with Intravenous Clevidipine Treatment) is a pilot study representing the first evaluation of safety and efficacy of intravenous clevidipine for the rapid treatment of hypertension in ICH patients. "
|5.||Renal Insufficiency (Renal Failure)
07/01/2009 - "Clevidipine controls intraoperative blood pressure in an adolescent with renal failure."
07/01/2009 - "In comparison to most other intravenous antihypertensives, clevidipine has a rapid onset of action, is ultra short-acting, easily titratable with a predictable dose response, and is void of drug-drug interactions and need for dose adjustment in patients with hepatic or renal insufficiency, thus making it a valuable antihypertensive in both the intraoperative and critical care settings. "
05/01/2002 - "These observations suggest that whereas both clevidipine and fenoldopam were potent natriuretic agents, only the calcium antagonist was effective in preserving renal function in the present experimental model of ischemic renal failure."
|2.||Calcium Channels (Calcium Channel)
|3.||Nitroprusside (Sodium Nitroprusside)
|10.||Antihypertensive Agents (Antihypertensives)
|1.||Length of Stay